Sublingual isoprenaline in treatment of primary pulmonary hypertension: discussion paper1 J F Ackroyd DSc FRCP St Mary's Hospital, London W2 JNY Primary pulmonary hypertension (PPH) is a rare disease which usually proves resistant to any form of therapy and most cases, however treated, run a relentlessly downhill course, ending fatally within a few years of the onset of symptoms (Alpert & Braunwald 1980 , Honey 1983 . Occasional cases run a more protracted course but spontaneous remission appears to have been reported only in two patients (Bourdillon & Oakley 1976 , Fujii et al. 1981 ). Although cases have been described in which a fall in pulmonary arterial pressure (PAP) developed in response to treatment with various vasodilator drugs (Wang et al. 1978 , Hermiller et al. 1982 , Rich et al. 1983a very few of these have experienced sustained improvement (Honey 1983 ). The vasodilator drug isoprenaline (ISP) has also usually failed to reduce PAP in cases of PPH (Hultgren & Shettigar 1978 , Belman et al. 1978 , Rich et al. 1983b , Daoud et al. 1978 . It is remarkable, therefore, that recently, exceptional cases have been reported which have responded well to long-term treatment with ISP administered sublingually, a route by which this drug is very poorly absorbed (see below). In such patients, sublingual ISP given several times a day has reduced PAP and improved exercise tolerance over periods of months or years (Shettigar et al. 1976 , Daoud et al. 1978 , Pantano 1980 , Lupi-Herrera et al. 1981 , Pietro et al. 1984 . In some cases increasing doses have had to be given to control the patients' symptoms (Daoud et al. 1978 , Pietro et al. 1984 , and even when the drug has continued to have an effect in reducing PAP, treatment has not always been associated with arrest of progression of the disease (Shettigar et al. 1976 ). In other cases, however, the effect of the drug in reducing PAP and improving symptoms has been maintained for remarkably long periods. Thus, Pietro and colleagues (1984) have described a patient in whom 10 mg ISP sublingually every two hours caused symptomatic relief, although subsequently this dose had to be given every one and a half hours. The patient's improvement was maintained on this regimen during a six-year period of observation. During this time there was only a slight rise in resting PAP when estimated immediately before the next dose of ISP was given, and 10 mg (later 20 mg) of ISP sublingually caused a striking fall in PAP each time this was investigated, the last occasion being four years after treatment was begun. Lupi-Herrera and colleagues (1981) have described two, somewhat similar, patients treated with sublingual ISP in whom the drug maintained PAP within almost normal limits over a three-year period of observation.
The pharmacological effects of ISP when administered sublingually are very much less than when the drug is given parenterally (Martindale 1982 ) and they are also variable (Weiner 1980 , Martindale 1982 . This is because, although a small amount of the drug is absorbed through the buccal mucosa, most of it is absorbed after being swallowed (D S Davies, unpublished) and is extensively metabolized during its passage through the intestinal mucosa (Dollery & Davies 1975 ). An indication of the inefficacy of the sublingual route of administration of ISP, even when given to patients with PPH who responded well to this form of treatment, is shown by the observation that in one of these patients (see below) 20 mg sublingually caused a reduction in PAP which was almost identical to that caused by an infusion of 3,g per minute into the pulmonary artery (Shettigar et al. 1976 ). In another patient who also responded well, 15 mg sublingually reduced PAP by about 30% in 20 minutes, whereas an intravenous infusion of 1.0,ug per minute reduced PAP by about 50% within two minutes (Daoud et al. 1978) . Information about patients who have responded well to sublingual ISP is limited, being contained almost exclusively in isolated case reports. However, because of the quite remarkable response of these patients to this very simple form of therapy for a disease which is usually completely resistant to treatment, an attempt is made below to analyse the available data about their responses and attention drawn to some observations which seem previously to have escaped comment.
That only a few patients with PPH have responded favourably to sublingual ISP raises the question whether these patients were abnormally reactive to this drug. Infusions of about I to 2 ,ug of ISP per minute intravenously into 6 normal (Dodge et al. 1960 , Paterson et al. 1968 and 5 asthmatic subjects who had not received bronchodilator therapy in the previous 12 hours (Warrell et al. 1970) caused increases in heart rates of 8-34 beats per minute.
Intravenous infusions of about 3 pg per minute into 2 of the asthmatic patients caused increases of 30 and 46 beats per minute (doses for asthmatic patients calculated for 70 kg body weight). In a patient with PPH who responded well to sublingual ISP (see below), the infusion of 3,ug per minute into the pulmonary artery increased the heart rate by 36 beats per minute (Shettigar et al. 1976 ). These figures suggest that abnormal sensitivity, at least to the chronotropic effect of ISP administered intravascularly, is not a prerequisite for the effective therapy of PPH with sublingual ISP.
The question must next be asked whether patients with PPH who respond well to sublingual ISP are abnormally sensitive to the drug when it is administered sublingually. They might, for instance, metabolize the drug in an unusual way to form an unidentified vasodilator metabolite, a possibility which is considered below. Alternatively, they might absorb the drug administered in this way abnormally well, in the sense that an abnormally high proportion of the drug reached the circulation in an active form having escaped metabolic degradation in the gut wall and the liver. In 8 normal subjects 15 mg of ISP sublingually caused a mean rise in pulse rate of 13.5 beats per minute, half of the rises being in the range of 20-31 beats per minute (Kaufman et al. 1951) . Of two patients with PPH who responded well to sublingual ISP, one developed a rise in heart rate of 17 beats per minute when given 10 mg sublingually (Pietro et al. 1984 ) and the other, whose response to an infusion of ISP into the pulmonary artery has just been quoted, developed a rise in heart rate of 18 beats per minute when given 20 mg sublingually (Shettigar et al. 1976 ). Neither patient had apparently previously received treatment with ISP which might have induced resistance to the chronotropic action of the drug (see below). The patient whose investigation, described above, showed that abnormal sensitivity to the chronotropic action of ISP was not essential for a favourable response to sublingual therapy, appeared to be normally sensitive to ISP administered into the pulmonary artery. This patient was one of the two whose responses to sublingual ISP have just been described. It seems, therefore, that not only was he normally sensitive to the drug given into the pulmonary artery where it could not have been significantly metabolized (see below) and, therefore, that he was normally sensitive to the drug itself, but that since he also responded normally to sublingual ISP, he must have absorbed it normally. Since the second patient also responded normally to the chronotropic action of ISP given sublingually, it seems probable that he also absorbed the drug normally and was normally sensitive to it. Alternative possibilities are that he was abnormally sensitive to the drug but absorbed it subnormally, or that he absorbed it abnormally well but was subnormally sensitive. These explanations both seem improbable. It seems most likely, therefore, that these patients were normally sensitive to the chronotropic action of ISP and that they absorbed it normally when it was administered sublingually. It must, however, be emphasized that these conclusions must await confirmation from investigations of further cases.
In the two patients just quoted, in whom sublingual ISP caused increases in heart rates of 17 and 18 beats per minute, these changes were accompanied respectively by falls in PAP from 50/25mmHg to 15/4mmHg (Pietro et al. 1984 ) and from 62/30mmHg to 36/10mmHg (Shettigar et al. 1976 ). In these patients, therefore, blood levels of ISP which were capable only of increasing the heart rates by 17 and 18 beats per minute reduced PAP to normal or practically normal levels. This is very surprising, since most patients with PPH have not developed any significant lowering of PAP even when given potent vasodilator drugs intravenously or into the pulmonary artery (Wood et al. 1982 , Rich et al. 1983a and, in fact, one of these two patients who responded well to sublingual ISP had failed to respond to intravenous hydralazine (Pietro et al. 1984) .
The interesting finding that a metabolite of ISP has some f,-adrenergic receptor antagonist activity (Paterson et al. 1968 , Dollery & Davies 1975 suggests the possibility, mentioned above, that this remarkable sensitivity to the action of ISP in lowering PAP might be due, in part, to an unidentified vasodilator metabolite formed after absorption of ISP administered sublingually. However, infusions of ISP into the pulmonary arteries of patients with PPH responsive to sublingual ISP have caused dramatic falls in PAP which could only have been due to ISP itself, since ISP when given into the pulmonary artery could not have been metabolized significantly before reaching the appropriate receptors (Rao et al. 1969 , Shettigar et al. 1976 , Pantano 1980 , Lupi-Hererra et al. 1981 . It seems virtually certain, therefore, that the rare patients with PPH who respond to sublingual ISP are extremely sensitive to its vasodilator activity and that, in these patients, the quite small quantities absorbed after sublingual administration that escape metabolic degradation are adequate to cause significant falls in PAP.
Patients treated regularly with ISP develop resistance to its cardioaccelerator activity (Paterson et al. 1968) . It is remarkable that although the patients with PPH who responded well to sublingual ISP had taken the drug in this way several times a day for months or years, often in increasing doses, they did not develop resistance to its action in lowering PAP. This suggests that they may have been protected from developing resistance in the same way that asthmatic patients appear to be protected from developing resistance to the bronchodilator effect of salbutamol (Harvey et al. 1981 , Harvey & Tattersfield 1982 which normal individuals develop (Holgate et al. 1980; Harvey & Tattersfield 1982) . One patient with PPH who continued to react to sublingual ISP with a fall in PAP over a period of several years did, however, develop resistance to the chronotropic action of the drug (Pietro et al. 1984) . Different tissues vary in the readiness with which they develop resistance to the pharmacological actions of sympathomimetic drugs (Anderson & Lees 1976 , Harvey et al. 1981 ), but the extreme disparity between the maintained effect of ISP in reducing PAP and the loss of its chronotropic effect in this patient is remarkable. However, not all patients with PPH are protected from developing resistance to the action of vasodilator drugs. Resistance to tolazoline (Rao et al. 1969 ) and nifedipine (Wood et al. 1982) has been reported to have developed remarkably quickly in patients with PPH in whom these drugs initially caused marked falls in PAP. It is interesting that in the patient in whom resistance developed to the action of nifedipine on PAP, this drug continued to cause a considerable fall in systemic arterial pressure.
As shown above, the dose of ISP given sublingually which was required to cause a satisfactory fall in PAP in patients with PPH was several thousand times greater than that required when the drug was given to the same patients intravenously (Daoud et al. 1978) or into the pulmonary artery (Shettigar et al. 1976) . Administration by inhalation is highly effective, at least as far as the chronotropic effect of the drug is concerned. Five healthy individuals developed rises in heart rates of 10-74 (mean 28) beats per minute when they inhaled one 'puff' from a Medihaler-Iso Forte (Riker Laboratories Limited) and they developed rises in heart rates of 28-58 (mean 44) beats per minute when they inhaled three 'puffs' (Paterson et al. 1968 ) (one 'puff' delivers approximately 400 ,ug ISP). As already stated, doses of sublingual ISP that reduced PAP to normal or practically normal levels in two patients with PPH (Pietro et al. 1984 , Shettigar et al. 1976 ) caused rises in their heart rates of 17 and 18 beats per minute. It therefore seems reasonable to conclude that the inhalation of one or two 'puffs' from a Medihaler-Iso Forte might have been equally effective in reducing PAP in these patients. ISP is more easily taken by inhalation than sublingually, since sublingual administration involves keeping a tablet under the tongue and trying to inhibit swallowing-for at least 10 minutes. In fact, it is difficult to see any justification for the continued use of this route of administration of ISP (see Ackroyd 1981) . For patients who find it difficult to inhale ISP from pressurized canisters, an alternative form of therapy which might be investigated is the oral ad-ministration of protokylol, a derivative of ISP which is said to be effective when given by mouth (Weiner 1980) .
To summarize, the response to sublingual ISP of this small group of patients with PPH has been sufficiently remarkable to make it clear that although many patients will not respond, treatment with ISP either sublingually or, probably preferably, by inhalation or possibly in the form of protokylol should be tried in every patient with this condition. This brief paper leaves many questions unanswered about the exceptional response of these patients. It does, however, show that although abnormal sensitivity to the chronotropic action of ISP was not apparently essential for a satisfactory therapeutic outcome, patients who responded well to sublingual ISP did seem to be extremely sensitive to its vasodilator action. Moreover, they were remarkable in that they did not develop resistance to this action. More detailed information than that contained in the case reports upon which this paper is based will be required before it will be possible to determine why some patients respond so well to the very small quantities of ISP absorbed after sublingual administration that escape metabolic degradation, when the majority of patients with PPH have shown no response to large doses of this and other vasodilator drugs given by more conventional routes. A plea is therefore made that future reports should contain the results of much more detailed investigations of such exceptional patients, including their response to inhaled ISP, in the hope that as these results and those of treatment with newer vasodilator drugs become available, a clearer picture may emerge and lead to a more effective form of therapy for this almost invariably fatal disease which tragically affects mainly adolescents and young adults.
